comparemela.com

Latest Breaking News On - Bioxytran chief medical - Page 1 : comparemela.com

Bioxytran Received IND Application by the FDA for Clinical Trials with ProLectin-M to Treat COVID-19 patients

"First Antiviral Drug in Glycovirology"BOSTON, MASSACHUSETTS - September 6, 2023 - BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and

United statesLeslie ajayiBioxytran incCompany nameDrug administrationAntiviral drugInvestigational new drugBioxytran chief medicalRelease distributedBioxytran receivedClinical trials

Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials

First Antiviral Drug in GlycovirologyBOSTON, MASSACHUSETTS, Aug. 24, 2023 (GLOBE NEWSWIRE) BIOXYTRAN, INC. (BIXT), (the “Company”), a clinica.

United statesMichael sheikhLeslie ajayiExchange commissionNuclear magnetic resonance spectroscopyBioxytran incCompany annual report on formDrug administrationFirst antiviral drugInvestigational new drugBioxytran chief medicalAnnual report

Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients

BOSTON, MASSACHUSETTS, Aug. 08, 2023 (GLOBE NEWSWIRE) BIOXYTRAN, INC. (BIXT), (the "Company"), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced the

United statesUnited kingdomLeslie ajayiMichael sheikhCentral drugs standard control organizationBioxytran incBioxytran chief medical

vimarsana © 2020. All Rights Reserved.